Treatment of Vascular Anomalies With Sirolimus: An Updated Comprehensive Review

Port J Card Thorac Vasc Surg. 2026 May 10;33(1):33-39. doi: 10.48729/pjctvs.614.ABSTRACTBACKGROUND: Sirolimus, an mTOR inhibitor, has transformed the management of complex slow- flow vascular malformations (VAMs), particularly those driven by PI3K/AKT/mTOR pathway activation. Evidence from prospecti

P Paulo Miguel Santos

Machine Learning Prediction Model for Dyslipidemia and Its Association With Atherothrombotic Events in 3 Independent Cohorts From South Korea, Japan, and the United Kingdom: Algorithm Development and Validation Study

JMIR Med Inform. 2026 May 19;14:e81130. doi: 10.2196/81130.ABSTRACTBACKGROUND: Dyslipidemia is a multifactorial and complex condition that warrants investigation through advanced analytical approaches such as machine learning (ML). Few previous ML studies predicting dyslipidemia have been validated

T Tae Hyeon Kim

Dyslipidaemias in cancer patients

Eur Heart J. 2026 May 19:ehag265. doi: 10.1093/eurheartj/ehag265. Online ahead of print.ABSTRACTDyslipidaemia in cancer patients presents several challenges with increasing survival of cancer patients. Dyslipidaemia and cancer treatments both increase atherosclerotic cardiovascular disease (ASCVD) r

M Muhummad Sohaib Nazir

Lipoprotein apheresis in the era of new lipid-lowering therapies

Eur Heart J. 2026 May 19:ehag328. doi: 10.1093/eurheartj/ehag328. Online ahead of print.ABSTRACTDuring the 1960s, in a pioneering way, plasmapheresis was used to treat children with homozygous familial hypercholesterolaemia (HoFH). Over the years, apheresis has evolved to increasingly selective meth

F Francesco Sbrana

Potential molecular targets on which methylene blue acts to promote its effects on cardiac electrophysiology, myocardial injury, and oxidative stress in spontaneously hypertensive rats submitted to cardiac ischemia and reperfusion

Acta Cir Bras. 2026 May 18;41:e411826. doi: 10.1590/acb411826. eCollection 2026.ABSTRACTPURPOSE: Although methylene blue (MB) has long been used to treat vasoplegic syndrome, its pharmacodynamics and cardiovascular effects remain unclear. Therefore, we decided to evaluate the potential molecular tar

R Rildo Yamaguti Lima

Myocardial YBX1 is dispensable for cardiac development and function

Am J Physiol Heart Circ Physiol. 2026 May 19. doi: 10.1152/ajpheart.00135.2026. Online ahead of print.ABSTRACTYBX1 is a DNA- and RNA-binding protein with multifaced roles in transcriptional, post-transcriptional, and translational regulation. Consequently, YBX1 controls many aspects of cellular func

E Elise V Stanley